Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders
NEW YORK--(BUSINESS WIRE)--Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No. 12/036,646. The title of the invention is Lisofylline Analogs and Methods for Use.